淫羊藿、黄芪、葛根有效组分复方对AD模型小鼠大脑皮质FPN1表达的影响

董贤慧; 高维娟; 赵家晴; 贺小平; 柴锡庆

淫羊藿、黄芪、葛根有效组分复方对AD模型小鼠大脑皮质FPN1表达的影响

1.
承德医学院解剖学教研室，河北承德 067000
2.
河北中医学院心脑血管病中医药防治重点实验室，河北石家庄 050000
3.
中国人民解放军第266医院骨科，河北承德 067000
4.
河北化工医药职业技术学院制药工程系，河北石家庄 050000

计量
- 文章访问数: 821
- HTML全文浏览量: 1
- PDF下载量: 695
- 被引次数: 0
出版历程
- 收稿日期: 2015-12-28
- 修回日期: 2016-01-17
- 刊出日期: 2016-03-10

Effects of Active Components of Epimedium， Astragalus and Radix Puerariae on the Expression of FPN1 in Cerebral Cortex in Alzheimer's Disease Model Mice

1.
Department of Human Anatomy, Chengde Medical University, Chengde, 067000, China
2.
Key Laboratory of Cardio-Cerebrovascular Disease Prevention and Control by Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200, China
3.
Department of Orthopaedics, The 266th Hospital of PLA, Chengde, 067000, China
4.
Department of Pharmaceutical Engineering, Hebei Chemcial and Pharmaceutial College, Shijiazhuang, 050000, China

摘要

摘要: 目的观察淫羊藿、黄芪、葛根有效组分复方对阿尔茨海默病（Alzheimer's disease，AD）APPswe/PS1dE9双转基因小鼠模型大脑皮质FPN1表达的影响。方法 6月龄雄性APPswe/PS1dE9双转基因小鼠60只，随机分为6组，模型组、淫羊藿组、黄芪组、葛根组、复方组、去铁胺(DFO)组，6月龄雄性C57BL/6J小鼠10只作为正常对照组。用药结束后，分别采用免疫组化、Real time PCR和Western blot方法检测各组小鼠大脑皮质FPN1的表达情况。结果阴性对照组均未见FPN1阳性细胞。与正常对照组比较，模型组FPN1的mRNA和蛋白表达降低（P<0.05）；与模型组比较，复方组和DFO组FPN1的mRNA和蛋白表达增高（P<0.05）；与DFO组比较，复方组FPN1的mRNA和蛋白表达无统计学差异（P>0.05），淫羊藿组、黄芪组、葛根组FPN1的mRNA和蛋白表达降低（P<0.05）。结论应用淫羊藿、黄芪、葛根有效组分复方可以上调AD模型小鼠大脑皮质FPN1的表达，从而抑制AD模型小鼠脑铁超载，缓解铁超载带来的中枢神经系统功能衰退。
- 阿尔茨海默病 /
- 淫羊藿 /
- 黄芪 /
- 葛根 /
- 有效组分 /
- 复方 /
- FPN1
Abstract: OBJECTIVE To investigate the effects of the active components of epimedium， astragalus and radix puerariae on FPN1 expression in the cerebral cortex of APPswe/PS1dE9 double transgenic Alzheimer's disease (AD) model mice. METHODS A total of 60 specific pathogen-free male APPswe/PS1dE9 double transgenic mice aged 6 months were equally and randomly divided into the model group， epimedium group， astragalus group， radix puerariae group， compound group and deferoxamine(DFO) group. Additional 10 of 6 months old C57BL/6J mice were chosen as normal control group. After the medication， the mouse brain tissue of every group were collected， and immunohistochemistry， Real time PCR and Western blot were used to detect the effects of active components of epimedium， astragalus and radix puerariae on FPN1 expression in the cerebral cortex of APPswe/PS1dE9 double transgenic mouse model of AD. RESULTS No FPN1 positional cells was observed in negative control group.The mRNA and protein expression of FPN1 decreased in the cerebral cortex of the model group（P<0.05）， compared with the control group. The mRNA and protein expression of FPN1 increased in the compound group and DFO group， compared to the model group. Compared to DFO group， no significant difference was observed in compounde group in the mRNA and protein expression of FPN1 in cerebral cortex; FPN1 mRNA expression decreased in the epimedium group， astragalus group and radix puerariae group. CONCLUSION Active components of epimedium， astragalus and radix puerariae can upregulate FPN1 expression and inhibit the ironoverload in the cerebral cortex of mice with Alzheimer's disease， which will mitigate the iron overload-induced impairment of the central nervous system.
- Alzheimer's disease /
- epimedium /
- astragalus /
- radix puerariae /
- active components /
- compound /
- FPN1

HTML全文

参考文献(21)

[1]	Suo WZ， Li L. Dysfunction of G Protein-coupled receptor kinases in Alzheimer's disease[J]. Sci World J， 2010， 10: 1667-1678.
[2]	孙祎敏，孔卫娜，李广志，等．铁超载促进阿尔采末病的发展及其相关治疗[J]．中国药理学通报，2010， 26（6）：824-827．
[3]	Sun YM， Kong WN， Li GZ， et al. High brain iron in etiology of Alzheimer's disease and therapeutic approaches[J]. Chin Pharmacol Bull， 2010， 26(6): 824-827.
[4]	Zhang LH， Wang X， Stoltenberg M， et al. Abundant expression of Zinc transporters in the amyloid plaques of Alzheimer's disease brain[J]. Brain Res Bull， 2008， 77(1): 55-60.
[5]	Kano O， Ikeda K， Iwasaki Y， et al. Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease[J]. Neurology， 2013，81(13):1181-1182
[6]	Kadir A， Andreasen N， Almkvist O， et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease[J].Ann Neurol，2008，63(5):621-631.
[7]	刘宝峰．阿尔茨海默病的中药治疗研究进展[J]．天津药学，2011， 23（1）：65-67．
[8]	Liu BF. Alzheimer's disease research progress of traditional Chinese medicine treatment[J]. Tianjin Pharm， 2011， 23(1): 65-67.
[9]	Yang YE， Shiao C， Hemingway JF， et al. Suppressed retinal degeneration in aged wild type and APP swe/PS1 delta E9 mice by bone marrow transplantation[J]. PLoS One， 2013， 8(6): e64246.
[10]	Kemppainen S， Hamalainen E， Miettinen PO， et al. Behavioral and neuropathological consequences of transient global ischemia in APP/PS1 Alzheimer model mice[J]. Behav Brain Res，2014，275:15-26.
[11]	方明娟，杨任民，吴君霞，等．铁代谢与神经变性性疾病[J]．中华临床医师杂志:电子版，2015， 9（7）：1201-1204．
[12]	Fang MJ， Yang RM， Wu JX， et al. Iron metabolism and neurodegenerative disease[J]. Chin J Clin: Electro， 2015， 9(7): 1201-1204.
[13]	Donovan A， Brownlie A， Zhou Y， et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter[J]. Nature，2000，403(6771):776-781.
[14]	McKie AT， Marciani P， Rolfs A， et al. A novel duodenal iron-regulated transporter，IREG1，implicated in the basolateral transferofiron to the circulation[J]. Mol Cell，2000，5(2):299-309.
[15]	Abboud S， Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism[J]. J Biol Chem，2000，275(26):19906-19912.
[16]	许珍晶．阿尔茨海默病临床研究进展[J]．中医药临床杂志，2014， 26（2）：194-196．
[17]	Xu ZJ. Clinical research progress of Alzheimer's disease[J]. Clin J Tradit Chin Med， 2014， 26(2): 194-196.
[18]	Gao J， Inagaki Y， Liu Y. Research progress on flavonoids isolated from traditional Chinese medicine in treatment of Alzheimer's disease[J]. Intractable Rare Dis Res， 2013， 2(1): 3-10.
[19]	Zhang L， Shen C， Chu J， et al. Icariin decreases the expression of APP and BACE-1 and reduces the beta-amyloid burden in an APP transgenic mouse model of alzheimer's disease[J]. Int J Biol Sci， 2014， 10(2): 181-191.
[20]	Sun Q， Jia N， Wang WX， et al. Protective effects of astragaloside IV against amyloid beta1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening[J]. PLoS One， 2014， 9(6): e98866.
[21]	Wang C， Xie N， Zhang H， et al. Puerarin protects against beta-Amyloid-induced microglia apoptosis via a PI3K-dependent signaling pathway[J]. Neurochem Res， 2014， 39(11): 2189-2196.